A Basic-clinical Translational Research in Hepatitis B Virus (HBV)-Specific Antigen Peptides and HepG2 Cell Lysate Co-activated Dendritic Cells Combined With Transarterial Chemoembolization (TACE) in HBV-related HCC Treatment (BTRHBVAPHCLCDCCTCHBVHCCT)

* Inclusion Criteria: * Patients with history of hepatitis B infection * Stage B or C in Barcelona Clinic Liver Cancer(BCLC) * Eastern Cooperative Oncology Group(ECOG) scores \<= 2.(without portal vein involved) * Patients have been unable to be performed surgery or liver transplant * Patients are appropriate to be performed TACE * 18 or over 18 years old * Patients haven't received radiation therapy or chemotherapy or immunotherapy * Normal renal function * Blood routine test:Hb\>=9g/L,white cell count\>=1.5\*10\^9/L,platelet count\>=50\*10\^9 * Liver function: bilirubin\<=50ummol/L,aspartate aminotransferase (AST) or alanine aminotransferase (ALT)\<=5 times the upper limit of normal * Child-Pugh score\<=9 * Human Chorionic Gonadotropin (HCG) test negative(-) if patients are women of reproductive ages * Women of reproductive ages promise to contracept until therapy course has been finished for 3 months * Patients who have signed up informed consents * Exclusion Criteria: * Extrahepatic metastasis of hepatocellular carcinoma * History of embolism, chemotherapy or radiation * History of major surgery in last 4 weeks * History of radiofrequency ablation in last 6 weeks * Acute infections in last 2 weeks * Child-Pugh scores\>9 * Patients with hepatic encephalopathy * Patients with ascites needed drainage * HCC with portal vein involved * Patients have history of cancer * Patients have history of HIV * Pregnant women * Patients with severe diseases like cardiac dysfunction * Patients with mental illness that influence signing informed consents * HBV infection combined with other types of hepatitis * Patients with autoimmune diseases * Immunosuppressant drugs users * Patients cannot follow our trial principle